• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

PsiOxus Therapeutics shuffles the deck

September 19, 2016 By drugdelivery

PsiOxus Therapeutics shuffles the deck


PsiOxus Therapeutics shuffles the deck
PsiOxus said it named Dr. Charles Morris as its chief development officer and Karen LaRochelle as its chief business officer.

Morris comes from ImmunoGen, where he was chief development officer, bringing its lead candidate to Phase III development. Most recently, LaRochelle was the executive director of global business development at Bristol Myers-Squibb. She worked as a consultant to PsiOxus and established a clinical collaboration between the 2 companies for Bristol Myer’s nivolumab and PsiOxus’ enadentucirev in solid tumors.

Oxford, U.K.-based PsiOxus also said it reorganized its executive team, promoting Dr. Brian Champion, formerly senior vice president for R&D, to chief scientific officer. Former CSO Dr. Kerry Fisher was named founding scientist and a member of the company’s scientific advisory board. COO Priya Mande was also named an executive director.

CFO Theodora Harold is stepping down to pursue other opportunities.

“I am delighted to welcome Karen and Charlie to reinforce our executive team at this key stage of our growth,” CEO Dr. John Beadle said in prepared remarks. “Charlie brings over 2 decades of oncology development expertise at a time that we are expanding our clinical stage activities in both the U.S. and Europe, whilst Karen’s impressive track record of over 50 successful transactions will be critical in achieving our portfolio strategy, which will be built upon a series of strategic collaborations using our T-SIGn platform. It is with sadness that we say goodbye to Theo and wish her every success in her new endeavors.”

Read more

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: Alphatec Holdings Inc., Integer Holdings, Personnel Moves, PsiOxus Therapeutics

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS